A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Guselkumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms VOYAGE 2
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 20 Feb 2018 According to a MorphoSys media release, data from this were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting
    • 20 Feb 2018 Results published in the MorphoSysMedia Release
    • 19 Feb 2018 According to the Janssen Pharmaceuticals media release, Prof. Kristian Reich, M.D. of Dermatologikum Berlin and SCIderm Research Institute, Hamburg, is the principal investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top